Welch & Forbes LLC Vertex Pharmaceuticals Inc Transaction History

Welch & Forbes LLC

$7.73 Billion
Q3 2024

A detailed history of Welch & Forbes LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Welch & Forbes LLC holds 196,619 shares of VRTX stock, worth $98.8 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares

196,619

Previous 194,897 0.88%

Holding current value

$98.8 Million

Previous $91.4 Million 0.1%

% of portfolio

1.18%

Previous 1.25%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	BUY	$460.0 - $505.78 $792,120 - $870,953	1,722 Added 0.88%	196,619 $91.4 Million
Q2 2024 Aug 01, 2024	BUY	$392.81 - $485.53 $768,336 - $949,696	1,956 Added 1.01%	194,897 $91.4 Million
Q1 2024 May 02, 2024	BUY	$407.69 - $446.08 $1.86 Million - $2.03 Million	4,554 Added 2.42%	192,941 $80.7 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $1.14 Million - $1.36 Million	3,317 Added 1.79%	188,387 $76.7 Million
Q3 2023 Nov 02, 2023	BUY	$338.18 - $362.46 $89,955 - $96,414	266 Added 0.14%	185,070 $64.4 Million
Q2 2023 Jul 28, 2023	SELL	$314.42 - $351.91 $444,589 - $497,600	-1,414 Reduced 0.76%	184,804 $65 Million
Q1 2023 Apr 14, 2023	SELL	$283.23 - $323.1 $553,148 - $631,014	-1,953 Reduced 1.04%	186,218 $58.7 Million
Q4 2022 Feb 02, 2023	SELL	$285.76 - $321.48 $367,773 - $413,744	-1,287 Reduced 0.68%	188,171 $54.3 Million
Q3 2022 Oct 28, 2022	SELL	$273.83 - $305.53 $759,878 - $847,845	-2,775 Reduced 1.44%	189,458 $54.9 Million
Q2 2022 Jul 22, 2022	SELL	$234.96 - $292.55 $781,242 - $972,728	-3,325 Reduced 1.7%	192,233 $54.2 Million
Q1 2022 Apr 25, 2022	BUY	$221.42 - $260.97 $1.25 Million - $1.47 Million	5,628 Added 2.96%	195,558 $51 Million
Q4 2021 Jan 19, 2022	SELL	$177.01 - $223.45 $2.14 Million - $2.71 Million	-12,107 Reduced 5.99%	189,930 $41.7 Million
Q3 2021 Oct 13, 2021	SELL	$181.39 - $202.99 $785,781 - $879,352	-4,332 Reduced 2.1%	202,037 $36.6 Million
Q2 2021 Jul 22, 2021	SELL	$187.49 - $221.1 $620,779 - $732,062	-3,311 Reduced 1.58%	206,369 $41.6 Million
Q1 2021 Apr 14, 2021	BUY	$207.02 - $241.31 $3.79 Million - $4.42 Million	18,312 Added 9.57%	209,680 $45.1 Million
Q4 2020 Jan 20, 2021	BUY	$207.01 - $276.09 $1.38 Million - $1.85 Million	6,686 Added 3.62%	191,368 $45.2 Million
Q3 2020 Oct 23, 2020	SELL	$255.65 - $303.1 $464,260 - $550,429	-1,816 Reduced 0.97%	184,682 $50.3 Million
Q2 2020 Jul 15, 2020	BUY	$225.48 - $295.8 $931,457 - $1.22 Million	4,131 Added 2.27%	186,498 $54.1 Million
Q1 2020 Apr 17, 2020	BUY	$199.77 - $247.81 $1.5 Million - $1.86 Million	7,499 Added 4.29%	182,367 $43.4 Million
Q4 2019 Jan 17, 2020	SELL	$166.71 - $223.91 $274,404 - $368,555	-1,646 Reduced 0.93%	174,868 $38.3 Million
Q3 2019 Oct 11, 2019	BUY	$166.23 - $187.09 $97,577 - $109,821	587 Added 0.33%	176,514 $29.9 Million
Q2 2019 Jul 12, 2019	BUY	$164.61 - $190.37 $243,128 - $281,176	1,477 Added 0.85%	175,927 $32.3 Million
Q1 2019 Apr 29, 2019	SELL	$163.73 - $194.7 $261,967 - $311,520	-1,600 Reduced 0.91%	174,450 $32.1 Million
Q4 2018 Feb 05, 2019	SELL	$151.91 - $192.21 $58,637 - $74,193	-386 Reduced 0.22%	176,050 $29.2 Million
Q3 2018 Oct 17, 2018	BUY	$167.73 - $192.74 $644,921 - $741,085	3,845 Added 2.23%	176,436 $34 Million
Q2 2018 Jul 16, 2018	SELL	$145.72 - $169.96 $648,454 - $756,322	-4,450 Reduced 2.51%	172,591 $29.3 Million
Q1 2018 Apr 12, 2018	SELL	$151.6 - $177.13 $183,739 - $214,681	-1,212 Reduced 0.68%	177,041 $28.9 Million
Q4 2017 Jan 26, 2018	SELL	$137.28 - $155.55 $332,354 - $376,586	-2,421 Reduced 1.34%	178,253 $26.7 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $26.8 Million - $29.3 Million	180,674	180,674 $27.5 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Welch & Forbes LLC, based on Form 13F filings with the SEC.

News

Stay updated on Welch & Forbes LLC with notifications on news.

Account